$CNTACentessa Pharmaceuticals plc

📅 Upcoming

🕒 Recent(90d)

News

• Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
  InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8…
  biospace · 6d ago
• Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
  After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
  fiercebiotech · 13d ago
• Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
  With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune…
  biospace · 1mo ago
• Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
  Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathogenic autoantibodies.
  fiercebiotech · 1mo ago
• ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
  As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
  fiercebiotech · 1mo ago
• Takeda leads wave of orexin drugs with potential to upend narcolepsy market
  The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
  biospace · 1mo ago
• Takeda approval ushers in new wave of sleep drugs
  An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.
  biopharma_dive · 1mo ago
• Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
  Foundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.
  biospace · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 1mo ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 2mo ago